(2-amino-4,5-dimethylthiophen-3-yl)(3-chlorophenyl)methanone | 247206-82-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: (2-amino-4,5-dimethylthiophen-3-yl)(3-chlorophenyl)methanone
• 英文别名: Methanone, (2-amino-4,5-dimethyl-3-thienyl)(3-chlorophenyl)-；(2-amino-4,5-dimethylthiophen-3-yl)-(3-chlorophenyl)methanone
• CAS: 247206-82-2
• 化学式: C₁₃H₁₂ClNOS
• 分子量: 265.763
• InChiKey: QKHSSAJIOBXMPU-UHFFFAOYSA-N

物化性质

• 沸点：
  441.4±45.0 °C(Predicted)
• 密度：
  1.303±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  71.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2-amino-4,5-dimethylthiophen-3-yl)(3-chlorophenyl)methanone 在 sodium hydride 、 对甲苯磺酸 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 26.0h， 生成 5-(3-chlorophenyl)-6,7-dimethyl-2-(methylthio)-3-(pyridin-3-ylmethyl)-3H-thieno[2,3-e][1,2,4]triazepine
  参考文献：
  名称：

  EP3640253

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(4,5-二甲基-2-噻吩)乙酮 在 氢氧化钾 、 五氯化磷 、 盐酸羟胺 、 四氯化锡 、 barium carbonate 作用下， 以 甲醇 、 乙醚 、 乙醇 、 1,2-二氯乙烷 为溶剂， 反应 20.0h， 生成 (2-amino-4,5-dimethylthiophen-3-yl)(3-chlorophenyl)methanone
  参考文献：
  名称：

  2-Amino-3-aroyl-4,5-alkylthiophenes:  Agonist Allosteric Enhancers at Human A₁ Adenosine Receptors

  摘要：

  2-Amino-3-benzoylthiophenes are allosteric enhancers (AE) of agonist activity at the A(1) adenosine receptor. The present report describes syntheses and assays of the AE activity at the human A(1)AR (hA(1)AR) of a panel of compounds consisting of nine 2-amino-3-aroylthiophenes (3a-i), eight 2-amino-3-benzoyl-4,5-dimethylthiophenes (12a-h), three 3-aroyl-2-carboxy-4,5-dimethylthiophenes (15a-c), 10 2-amino-3-benzoyl-5,6-dihydro-4H-cyclopenta[b]thiophenes (17a-j), 14 2-amino-3-benzoyl-4,5,6,7-tetrahydrobenzo[b]thiophenes (18a-n), and 15 2-amino-3-benzoyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophenes (19a-o). An in vitro assay employing the A(1)AR agonist [I-125]ABA and membranes from CHO-K1 cells stably expressing the hA(1)AR measured, as an index of AE activity, the ability of a candidate AE to stabilize the agonist-A(1)AR-G protein ternary complex. Compounds 3a-i had little or no AE activity, and compounds 12a-h had only modest activity, evidence that AE activity depended absolutely on the presence of at least a methyl group at C-4 and C-5. Compounds 17a-c lacked AE activity, suggesting the 2-amino group is essential. Polymethylene bridges linked thiophene C-4 and C-5 of compounds 17a-j, 18a-n, and 19a-o. AE activity increased with the size of the -(CH2)(n)- bridge, n = 3 < n = 4 < n = 5. The 3-carbethoxy substituents of 17a, 18a, and 19a did not support AE activity, but a 3-aroyl group did. Bulky (or hydrophobic) substituents at the meta and para positions of the 3-benzoyl group and also 3-naphthoyl groups greatly enhanced activity. Thus, the hA(1)AR contains an allosteric binding site able to accommodate 3-aroyl substituents that are bulky and/or hydrophobic but not necessarily planar. A second region in the allosteric binding site interacts constructively with alkyl substituents at thiophene C-4 and/or C-5.

  DOI：

  10.1021/jm010081p

文献信息

• 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE
  申请人：AYUMI Pharmaceutical Corporation

  公开号：EP3640253A1

  公开（公告）日：2020-04-22

  The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

  本发明的 6H-噻吩并[2,3-e][1,2,4]三唑并[3,4-c][1,2,4]三氮杂卓衍生物或其盐类具有 BRD4 抑制活性，因此可用作药物，特别是用作与 BRD4 相关疾病的预防和/或治疗药物。
• 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative
  申请人：AYUMI PHARMACEUTICAL CORPORATION

  公开号：US11186588B2

  公开（公告）日：2021-11-30

  The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

  本发明的 6H-噻吩并[2,3-e][1,2,4]三唑并[3,4-c][1,2,4]三氮杂卓衍生物或其盐类具有 BRD4 抑制活性，因此可用作药物，特别是用作与 BRD4 相关疾病的预防和/或治疗药物。
• Allosteric Modulation of the Adenosine A₁ Receptor. Synthesis and Biological Evaluation of Novel 2-Amino-3-benzoylthiophenes as Allosteric Enhancers of Agonist Binding
  作者：Pieter A. M. van der Klein、Angeliki P. Kourounakis、Ad P. IJzerman

  DOI：10.1021/jm991051d

  日期：1999.9.1

  Novel allosteric enhancers of agonist binding to the rat adenosine Al receptor are described. The lead compound for the new series was PD 81,723 ((2-amino-4,5-dimethyl-3-thienyl)[3(trifluoromethyl)phenyl]methanone), a compound previously reported by Bruns and co-workers (Mol. Pharmacol. 1990, 38, 950-958). The 4,5-dimethyl group and the benzoyl moiety were targets for further modifications, leading to series of 4,5-dialkyl (12a-g), of tetrahydrobenzo (12h-u), and of tetrahydropyridine (13a-g) derivatives. A number of compounds, in particular 12b, 12e, 12j, 12n, and 12u, proved superior to PD 81,723, Their EC50 values for enhancing the binding of the adenosine Al receptor agonist N-6-cyclopentyladenosine to the receptor were lower, and/or their antagonistic activity on the adenosine Al receptor was shown to be diminished.
• SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR COMPOUNDS
  申请人：Brussee Johannes

  公开号：US20100317709A1

  公开（公告）日：2010-12-16

  The invention relates to compounds, in particular 2-amino-3,4,5,-trisubstituted thiophenes, pharmaceutical compositions containing them and the uses of said compounds and compositions for diseases related to sphingosine-1-phosphate (S1P) receptors, predominantly S1P3 receptors. The diseases include cardiovascular diseases, atherosclerosis, cancer, pulmonary oedema, autoimmune disorders and Adult Respiratory Distress Syndrome.
• 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE
  申请人：AYUMI PHARMACEUTICAL CORPORATION

  公开号：US20210130367A1

  公开（公告）日：2021-05-06

  The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.